These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8850386)

  • 1. Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):809-14. PubMed ID: 8850386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Nagai R
    Res Commun Mol Pathol Pharmacol; 1996 Jan; 91(1):17-32. PubMed ID: 8824928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Eur J Pharmacol; 1996 Jan; 295(2-3):229-34. PubMed ID: 8720589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Sumino H; Kobayashi I; Iwamoto A; Nagai R
    Life Sci; 1998; 63(10):PL137-43. PubMed ID: 9734710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Suzuki T; Kobayashi I; Kodama K; Nagai R
    Life Sci; 1996; 59(23):PL 371-7. PubMed ID: 8950302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
    Wang Y; Hu F; Mu X; Wu F; Yang D; Zheng G; Sun X; Gong K; Zhang Z
    Biorheology; 2016 Jan; 53(1):13-22. PubMed ID: 26889655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
    Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats.
    Ono M; Sawa Y; Fukushima N; Suhara H; Nakamura T; Yokoyama C; Tanabe T; Matsuda H
    Eur J Cardiothorac Surg; 2004 Dec; 26(6):1092-7. PubMed ID: 15541968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.
    Miyauchi T; Yorikane R; Sakai S; Sakurai T; Okada M; Nishikibe M; Yano M; Yamaguchi I; Sugishita Y; Goto K
    Circ Res; 1993 Nov; 73(5):887-97. PubMed ID: 8403258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sandostatin inhibits development of medial proliferation of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Murata K
    Life Sci; 1995; 57(8):PL91-5. PubMed ID: 7637546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
    Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocrotaline-induced structural remodeling of the intra-acinar pulmonary arteries and pulmonary hypertension.
    Li WY; Che DY
    J Tongji Med Univ; 1992; 12(4):227-33. PubMed ID: 1289571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
    Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
    Li FH; Xia W; Li AW; Zhao CF; Sun RP
    Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats.
    Chang CY; Shih HJ; Huang IT; Tsai PS; Chen KY; Huang CJ
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
    Kang KK; Ahn GJ; Sohn YS; Ahn BO; Kim WB
    J Int Med Res; 2003; 31(6):517-28. PubMed ID: 14708417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Ca2+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension.
    Pereira SL; Kummerle AE; Fraga CA; Barreiro EJ; Rocha Nde N; Ferraz EB; do Nascimento JH; Sudo RT; Zapata-Sudo G
    Eur J Pharmacol; 2013 Feb; 702(1-3):316-22. PubMed ID: 23399770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.